Want to create an interactive transcript for this episode?
Podcast: North Star with Ellin Bessner
Episode: One step closer to a cure for Alzheimer's? A Canadian expert weighs in
Description: Last June, the American Food and Drug Administration conditionally approved aducanumab, marketed as Adulehm, to treat those suffering from early Alzheimer's and other forms of dementia. It's the first drug in nearly 20 years to gain some kind of approval, even though other countries' health agencies, including Canada's, are still reviewing the data. There are concerns the drug causes brain bleeding and swelling, and may not be an effective treatment.
Nonetheless, it's a massive step forward for a disease that affects at least 44 million people worldwide, including 750,000 Canadians, with real patients taking the drug in clinical trials right...